Concepedia
Statistics
Publications
3
Citations
580
H-Index
Active since
2007
Affiliations
Memorial Sloan Kettering Cancer Center(Current)
Massachusetts General Hospital
Seoul National University Hospital
Kettering University
Samsung Medical Center
Juliet Liu is an author at Memorial Sloan Kettering Cancer Center specializing in oncology, medicine, and tyrosine kinase inhibitors.
Publications per year
2007–2019
Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations
Alexander Drilon, Sai‐Hong Ignatius Ou, Byoung Chul Cho et al. · Cancer Discovery · 2018 · 480 citations · Full text
Medicine, Oncology, Pharmacology +15
Erythropoietin, a hypoxia-regulated factor, elicits a pro-angiogenic program in human mesenchymal stem cells
Kevin J. Zwezdaryk, Seth B. Coffelt, Yanira G. Figueroa et al. · Experimental Hematology · 2007 · 72 citations · Full text
Life Sciences, Cell Biology, Physiology +15
Abstract 442: Repotrectinib, a next generation TRK inhibitor, overcomes TRK resistance mutations including solvent front, gatekeeper and compound mutations
Alexander Drilon, Dayong Zhai, Wei Deng et al. · Cancer Research · 2019 · 28 citations
Medicine, Oncology, Pharmacology +17
1–3 of 3